Company intelligence / Profile preview

Bopin (Shanghai) Biomedical Technology

Shanghai, Shanghai Shi, Chinazjbsled.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company has initiated a Phase I clinical trial to evaluate the safety, tolerability, and preliminary efficacy of allogeneic adipose-derived mesenchymal stem cells in knee osteoarthritis. The primary goal of the study is to establish safety and recommend a dose range for further studies; secondary endpoints include initial assessment of efficacy. No published results are available as of the latest update.

Therapeutic areas: DermatologyRheumatology
Modalities: Mesenchymal stem cell therapyBiological products
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Bopin (Shanghai) Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bopin (Shanghai) Biomedical Technology.

Explore the full profile